- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03744871
Air Pollution: Strategies for Personalized Intervention to Reduce Exposure (ASPIRE)
ASPIRE: Air Pollution: Strategies for Personalized Intervention to Reduce Exposure
Study Overview
Detailed Description
CLEANAIR-ACS will be an investigation within ASPIRE, that will test the ability of personal-level intervention (N95 respirators) to improve validated surrogate markers of cardio-metabolic health in patients with a recent Acute Coronary Syndrome (ACS). Patients with ACS are a vulnerable patient population with vulnerability and at risk for future cardiovascular events. This vanguard phase study in Beijing involving patients exposed to high levels of air pollution who have recently sustained an ACS event, is necessary to obtain feasibility data and gather a battery of information allowing for the appropriate design of a larger clinical outcome trial. What is more, positive results would provide critically-important information demonstrating for the first time that it is feasible to "prescribe" the use of these personal protection devices to cardiac patients, and that their usage is capable of translating into demonstrable health benefits (i.e., improved BP and insulin sensitivity) over the long-term.
The study hypothesis is that long-term personal-level interventions to reduce exposure to PM2.5 can be feasibly performed for 1-year post-acute coronary syndrome (ACS) and will result in significant improvements in validated surrogate cardiometabolic endpoints predictive of morbidity/mortality.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Beijing, China
- Peking University
-
-
-
-
Ohio
-
Cleveland, Ohio, United States, 44106
- University Hospitals Cleveland Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female >18, able to provide informed consent and willingness to complete the study protocol and measurement procedures, AND
- Non-smoker of any type (cigarette, cigar, marijuana) during past six months (100% abstinence per self-report) and living in a non-smoking household (no person living in the household smoking at home) with confirmation of non-smoking status by urinary cotinine levels.
AND 3. A diagnosis of myocardial infarction or unstable angina 7-90 days prior to signed informed consent
Exclusion Criteria:
- Inability for mental or physical reasons to understand and comply with the informed consent process and/or the study protocol procedures including wearing face mask (i.e: advanced COPD/lung disease requiring use of frequent inhalational or nebulizer treatments) per investigator discretion.
- Obesity with arm circumference >18 inches preventing accurate BP determination during ABPM monitoring
- Significant hemodynamically unstable CV disorder including uncompensated heart failure, refractory angina, uncontrolled arrhythmias, critical valvular heart disease and severe hypertension. (as further described in Appendix B) at screening
- ESRD on dialysis or patients that have received dialysis within 14 days prior to screening
- Subject has a history of infection with human immunodeficiency virus
- Subject has a history of alcohol or substance abuse within the 6 months prior to the screening
- Advanced COPD on home oxygen
- Past diagnosis of sleep apnea either untreated or treated with CPAP
- History of malignancy including leukemia and lymphoma (but not basal cell skin cancer, cured squamous cell cancer and localized Prostate cancer) AND/OR any severe, life-threatening disease AND/OR history of drug abuse within the last 2 years
- Regular use of any over-the-counter drug, recreational medication including stimulants (amphetamines) and/or complimentary or herbal therapy that might impact study outcomes including BP and insulin sensitivity per investigator discretion.
- In women of childbearing age: pregnancy, non-use of approved method of birth control, intent to get pregnant during the study period
- Patients with passive home cigarette smoking
Other medical or psychosocial conditions or life circumstances that may put the subject at increased risk of participation or jeopardizes the scientific integrity of the study, as determined by the investigators
-
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Respirator
Open label use of N95 respirators (worn outdoors) (active limb, n=100)
|
SiTi N95 respirator with microventilator (change twice weekly and earlier as needed).
|
No Intervention: No intervention
No respirators will be worn by the control group (control limb, n=100)
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood Pressure
Time Frame: 12 months
|
Use Omron 907xl for clinic BP Measures, with 3 repeated measurements after 5 minutes after clinicians leave room (patient unattended).
Averages of the 3 BP Recordings will be obtained
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
PWV and pulse wave analysis
Time Frame: 12 months
|
To be measured at clinic visits, with Omron used in JI Study
|
12 months
|
BP/HRV Monitoring
Time Frame: 12 months
|
24 hour ambulatory HRV/BP will be placed when clinic BP is complete as the first clinic measure.
The monitoring systems have been used in JI study previously
|
12 months
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 03-18-20
- R01ES019616 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Air Pollution
-
U.S. EPA Human Studies FacilityRecruitingAir PollutionUnited States
-
UConn HealthNational Institute of Environmental Health Sciences (NIEHS)Completed
-
Stanford UniversityDuke University; National Institute of Environmental Health Sciences (NIEHS)CompletedPregnancy | Air PollutionUnited States
-
Environmental Protection Agency (EPA)Enrolling by invitationAir Pollution | Pollution; Exposure | Nutrition, HealthyUnited States
-
University of LouisvilleNational Institute of Environmental Health Sciences (NIEHS)Completed
-
Rutgers, The State University of New JerseyNational Institute of Environmental Health Sciences (NIEHS)Completed
-
University of MichiganCompletedAir PollutionUnited States
-
Rutgers, The State University of New JerseyCompleted
-
University of Southern CaliforniaDuke UniversityRecruiting
-
University of Colorado, DenverNational Institutes of Health (NIH); University of Colorado, Boulder; U.S. National... and other collaboratorsCompletedHousehold Air Pollution | Behavior, Social
Clinical Trials on N95 Respirator
-
McMaster UniversityUniversity of AlbertaCompletedCoronavirus | N95 | Medical MaskCanada, Egypt, Israel, Pakistan
-
University of ArkansasCompleted
-
Wake Forest University Health SciencesFree AirCompleted
-
University of BrasiliaUniversity of Campinas, Brazil; Centro de Pesquisa em Biotecnologia Ltda; Hospital...CompletedCovid19 | SARS-CoV Infection | Worker-Patient Transmission, HealthcareBrazil
-
Johns Hopkins UniversityDuke University; National Institutes of Health (NIH); Fogarty International Center... and other collaboratorsRecruiting
-
Johns Hopkins UniversityChildren's Hospital Colorado; US Department of Veterans Affairs; Centers for... and other collaboratorsCompletedParamyxoviridae Infections | Influenza | Coronavirus | Respiratory Syncytial Viruses | RhinovirusUnited States
-
Fudan UniversityCompletedInflammation | Blood Coagulation Disorders | Blood Pressure | Vasoconstriction | Autonomic Nervous System ImbalanceChina
-
Fraunhofer-Institute of Toxicology and Experimental...Completed
-
University of EdinburghPeking Union Medical CollegeCompletedBlood Pressure | Heart Rate VariabilityChina
-
National University Health System, SingaporeCompleted